Dr. Weidhaas, a co-founder of MiraDx and professor at UCLA, leads translation research in radiation oncology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology, and treatment response. She co-founded MiraDx and MiraKind to empower individuals with meaningful health information. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center and previously served as Chief of the Breast Cancer Radiation Service at Yale Cancer Center. She completed an MSM at Stanford University during a sabbatical at Yale. She moved to UCLA as Professor and Division Head, Translational Research, in 2014. Her dual role as a clinician and researcher applies genetic breakthroughs to patient benefit. She currently resides in the LA area with her husband and three children.